Yahoo Finance • 28 days ago
Results from long-term follow up of patients treated with atrioventricular interval modulation (“AVIM”) therapy show blood pressure-lowering effects are sustained for years after activation, reversible with no observed rebound hypertension... Full story
Yahoo Finance • last month
Data from acute and chronic pressure-volume loop studies support the mechanism of action and show a favorable impact of AVIM therapy on blood pressure and cardiovascular hemodynamicsAVIM therapy drove statistically significant reductions i... Full story
Yahoo Finance • 2 months ago
NEW HOPE, Pa. - Orchestra BioMed Holdings, Inc. (Nasdaq:OBIO), a medical technology company with a market capitalization of $143.5 million and impressive gross profit margins of 92.7%, announced Thursday that a new study published in JACC:... Full story
Yahoo Finance • 2 months ago
* Orchestra BioMed press release [https://seekingalpha.com/pr/20197531-orchestra-biomed-reports-second-quarter-2025-financial-results-and-highlights-recent-business] (NASDAQ:OBIO [https://seekingalpha.com/symbol/OBIO]): Q2 GAAP EPS of -$... Full story
Yahoo Finance • 2 months ago
Secured over $111 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by over $71 million in committed capital from Medtronic and LigandAchieved m... Full story
Yahoo Finance • 2 months ago
FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT global pivotal study (“BACKBEAT study”), resulting in an estimated more than 24-fold increase in the potentially eligible patient pool as comp... Full story
Yahoo Finance • 2 months ago
Director David P. Hochman of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has recently purchased 20,000 shares of the company’s common stock at $2.75 per share, according to a Form 4 filing with the Securities and Exchange Commission. The... Full story
Yahoo Finance • 2 months ago
NEW HOPE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing part... Full story
Yahoo Finance • 2 months ago
• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to invest $10 million in an equity private p... Full story
Yahoo Finance • 3 months ago
Presentation underscores unique potential for atrioventricular interval modulation (“AVIM”) therapy to manage blood pressure in older, high-risk patients who have indicators of diastolic dysfunction and progression to heart failure with pr... Full story
Yahoo Finance • 5 months ago
Secured ten new fully-issued patents related to hypertension treatment during last 12 months, bringing global issued patent estate total for this condition to 120 patentsPatent estate covering atrioventricular interval modulation (“AVIM”)... Full story
Yahoo Finance • 5 months ago
FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular riskHRS Satellite Symposium will feature leading experts in electrophysiology, hypertension... Full story
Yahoo Finance • 5 months ago
Breakthrough Device Designation (“BDD”) applies to an estimated U.S. population of over 7.7 million patients with uncontrolled hypertension and increased cardiovascular riskBDD also encompasses pacemaker-indicated patients with uncontrolle... Full story
Yahoo Finance • 6 months ago
NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward... Full story
Yahoo Finance • 7 months ago
The BACKBEAT global pivotal study is currently enrolling patients to evaluate the efficacy and safety of atrioventricular interval modulation (“AVIM”) therapy for patients who have uncontrolled hypertension and a pacemaker indicationA glob... Full story
Yahoo Finance • 8 months ago
Late-breaking oral presentation features echocardiographic data analysis showing favorable impact of AVIM therapy on MODERATO II study patients with diastolic dysfunction, a key component in the development of heart failureHypertension is... Full story
Yahoo Finance • 8 months ago
Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development (“R&D”) collaborations aligned with Orchestra BioMed’s partnership-enabled business model Mr. Cleary previously s... Full story
Yahoo Finance • 2 years ago
U.S. FDA granted Investigational Device Exemption (“IDE”) approval to initiate the BACKBEAT pivotal study evaluating AVIM therapy (BackBeat CNT) in hypertensive pacemaker patients BACKBEAT pivotal study on track to start enrollment before... Full story
Yahoo Finance • 2 years ago
NEW HOPE, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing par... Full story
Yahoo Finance • 2 years ago
Hypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually worldwideMedtronic plc and Orchestra BioMed have an exclusive strategic collaboration for glob... Full story